REL.L - RELX PLC

LSE - LSE Delayed Price. Currency in GBp
1,922.50
+34.00 (+1.80%)
As of 2:04PM BST. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1,888.50
Open1,890.50
Bid1,921.50 x 0
Ask1,922.50 x 0
Day's Range1,875.50 - 1,925.00
52 Week Range1,382.86 - 2,109.00
Volume990,155
Avg. Volume6,420,844
Market Cap37.13B
Beta (5Y Monthly)0.29
PE Ratio (TTM)25.00
EPS (TTM)76.90
Earnings DateJul 23, 2020
Forward Dividend & Yield0.46 (2.42%)
Ex-Dividend DateApr 24, 2020
1y Target Est1,738.50
  • LexisNexis Risk Solutions Positioned as a Leader in Risk-Based Authentication Report
    PR Newswire

    LexisNexis Risk Solutions Positioned as a Leader in Risk-Based Authentication Report

    LexisNexis® Risk Solutions is honored to announce it is named as a leader among risk-based authentication (RBA) providers in The Forrester Wave™: Risk-Based Authentication, Q2 2020 report. Forrester positioned LexisNexis Risk Solutions as having the highest score in the strategy category among all vendors included in the report.

  • LexisNexis Risk Solutions Insurance Demand Meter Provides Initial Glimpse Into COVID-19 Impact on U.S. Auto Insurance Shopping Activity
    PR Newswire

    LexisNexis Risk Solutions Insurance Demand Meter Provides Initial Glimpse Into COVID-19 Impact on U.S. Auto Insurance Shopping Activity

    LexisNexis® Risk Solutions released today the Q2 2020 Insurance Demand Meter, which highlights trends from Q1, and also reveals how the coronavirus pandemic is impacting U.S. consumer auto insurance shopping though April 2020. According to the Meter, shopping events have closely mirrored other national developments with the pandemic – from a marked decrease correlated to the stay-at-home orders to an increase that appears to coincide with the timing of the federal stimulus checks1. The report additionally highlights COVID-19's impact by age group, geography and shopping channel.

  • Estimating The Intrinsic Value Of RELX PLC (LON:REL)
    Simply Wall St.

    Estimating The Intrinsic Value Of RELX PLC (LON:REL)

    Does the May share price for RELX PLC (LON:REL) reflect what it's really worth? Today, we will estimate the stock's...

  • A Pandemic Moves Peer Review to Twitter
    Bloomberg

    A Pandemic Moves Peer Review to Twitter

    (Bloomberg Opinion) -- Last June, the Cold Spring Harbor Laboratory on Long Island, Yale University and The BMJ (formerly the British Medical Journal) started a new “preprint server” for medical research called MedRxiv. Preprint is one term of art for an academic paper that hasn’t been peer reviewed or published yet. Working paper is another. They’ve been distributed at meetings and seminars as long as anyone can remember. In 1991, physicists began sharing theirs on the internet on a server that came to be called ArXiv (pronounced “archive”).(1) Mathematicians, astronomers, economists and scholars in a few other disciplines soon followed suit — some on ArXiv, some on other sites.Medical researchers did not. For one thing, peer-reviewed biomedical journals publish research findings faster than those in some other fields (average time to publication is half what it is in business and economics), so the need for a speedy alternative was less pronounced. For another, medical research often involves questions of life or death that presumably deserve more pre-publication scrutiny than, say, a theoretical physics paper. And given that publishing in prestigious journals is key to career advancement, and prestigious medical journals have long made a big deal about having exclusives on new research results, researchers had legitimate worries that releasing results earlier could hurt them.Things started off unsurprisingly slowly for MedRxiv last summer, and there wasn’t all that much sign of an acceleration over the course of 2019. Then a new coronavirus began infecting people in Wuhan, China, and, well, you can probably guess what happened next:Page views to the MedRxiv site are now averaging 15 million a month, up from 1 million before the pandemic. Something significant has changed in medical research.Many of the coronavirus-related papers being posted on MedRxiv are rushed and flawed, and some are terrible. But a lot report serious research findings, some of which will eventually find their way into prestigious journals, which have been softening their stance on previously released research. (“We encourage posting to preprint servers as a way to share information immediately,” emails Jennifer Zeis, director of communications at the New England Journal of Medicine.) In the meantime, the research is out there, being commented on and followed up on by other scientists, and reported on in the news media. The journals, which normally keep their content behind steep paywalls, are also offering coronavirus articles outside of it. New efforts to sort through the resulting bounty of available research are emerging, from a group of Johns Hopkins University scholars sifting manually through new Covid-19 papers to a 59,000-article machine-readable data set, requested by the White House Office of Science and Technology Policy and enabled by an assortment of tech corporations and academic and philanthropic organizations, that is meant to be mined for insights using artificial intelligence and other such means.This is the future for scientific communication that has been predicted since the spread of the internet began to enable it in the early 1990s (and to some extent long before then), yet proved slow and fitful in its arrival. It involves more or less open access to scientific research and data, and a more-open review process with a much wider range of potential peers than the peer review offered by journals. For its most enthusiastic boosters, it is also an opportunity to break through disciplinary barriers, broaden and improve the standards for research success and generally just make science work better. To skeptics, it means abandoning high standards and a viable economic model for research publishing in favor of a chaotic, uncertain new approach.I’m mostly on the side of the boosters here, but have learned during five years of writing on and off about academic publishing that the existing way of doing things is quite well entrenched, and that would-be innovators often misunderstand the challenges involved in displacing or replacing it. This moment does feel different, though. “It’s going to really be fascinating to see if this will be the tipping point,” says Heather Joseph, executive director of the Scholarly Publishing and Academic Resources Coalition, an organization of academic libraries that has been pushing hard for a more open research infrastructure. “Because of the way distribution of scientific information is being piloted in a new way in the Covid crisis, my hope is that this will spill over to other areas in subsequent years,” adds Ijad Madisch, a German virologist who is founder and chief executive of ResearchGate, a social network for researchers that has seen a surge in activity and collaboration around Covid-19. “It scares me that we as scientists might just go back to doing things as we did before.”A ‘Scoop-Protection Device’At MedRxiv, co-founder Richard Sever is pretty sure that medical researchers won’t be turning away from preprints after the crisis has passed. “Once a field starts doing this, they don’t stop,” he says. Sever is assistant director of the Cold Spring Harbor Laboratory Press and also co-founder of BioRxiv, MedRxiv’s sister preprint server, which he has watched catch on with one biology subfield after another (first genomics, then cell biology, most recently neuroscience) since its founding in 2013. BioRxiv has also seen a recent surge in submissions and readership, albeit less dramatic than MedRxiv's given that it was starting from a much larger base.A big part of the attraction of preprints for researchers studying a fast-moving phenomenon such as Covid-19 is that they rather than journal editors control the timing of the release of new research results. “It’s a scoop-protection device,” Sever says. Other major destinations for coronavirus-related preprints include Research Square, Preprints.org and the Center for Open Science’s OSF Preprints. Overall, there were at least 8,830 biomedical preprints posted in March, up 142% from March 2019, according to data compiled by Jessica Polka and Naomi Penfold of the nonprofit Accelerating Science and Publication in Biology (aka ASAPbio).BioRxiv and MedRxiv don’t accept every submission. Pure opinion pieces aren’t allowed — there has to be actual research involved. Beyond that, says Sever, “if something goes up on BioRxiv it just means we don’t think it’s dangerous and it’s probably not crazy nonsense,” while for MedRxiv there’s heightened scrutiny of potentially dangerous claims plus a checklist of conditions that any clinical research paper must satisfy. Both servers also recently began declining papers that pointed to treatments for the coronavirus based purely on computer modeling. “We decided that somewhere on this spectrum was a point where peer review was needed,” Sever says.This came as something of a shock to Albert-László Barabási, a prominent network scientist at Northeastern University in Boston who had a paper on a “Network Medicine Framework for Identifying Drug Repurposing Opportunities” rejected last month by BioRxiv. He eventually just posted it on ArXiv instead, but wondered on Twitter if it might make more sense for BioRxiv to create a scientists-only list for potentially sensitive Covid-19 research. ResearchGate’s Madisch also likes the idea of a setup “where the research community can give feedback before it’s released to the public,” but Sever said he worries that such an approach would just end up favoring an in-crowd of scientists at top universities.So for now, at least, it’s all happening in public. One oft-heard complaint is that this allows unvetted research to be distributed to lay readers — as with the paper posted on BioRxiv in late January that found an “uncanny similarity” between several genetic sequences in the new coronavirus and those in the human immunodeficiency virus that causes AIDS, findings that as BuzzFeed News science reporter Stephanie M. Lee described in an account of the paper’s rise and fall were immediately latched onto online as evidence that the virus was man-made. After other researchers tweeted criticism that the findings were in fact probably the product of random chance, though, the authors retracted the paper.Clearly, preprint servers can allow bad information to be presented to the public. But research findings published in peer-reviewed journals have to be retracted sometimes, too, and many more turn out to be wrong in the sense that they can’t be replicated by subsequent studies. As Stanford Medical School’s John Ioaniddis argued in a 2005 paper so famous that it has its own Wikipedia page, “most published research findings are false.”That brings us to perhaps the most vigorously debated MedRxiv paper so far, “COVID-19 Antibody Seroprevalence in Santa Clara County, California,” posted on the site April 17 by a multidisciplinary team of authors that included Ioaniddis. The paper reported the results of testing for coronavirus antibodies among 3,300 county residents recruited by Facebook ads, 1.5% of whom tested positive. The authors then made a number of statistical adjustments that upped their estimate of the percentage of county residents who had been infected with the coronavirus to 2.49% to 4.16%, which was 50 to 80 times the number of confirmed cases at the time and implied a Covid-19 fatality rate of just 0.12 to 0.2% — not all that different from the rates usually reported for seasonal influenza (although the actual ratio of influenza fatalities to infections is probably lower).Some infectious disease experts, whose estimates of Covid-19’s infection fatality rate have mostly centered on a range of about 0.5% to 1%, took to Twitter to offer skeptical but reasonably polite critiques. (Disclosure: so did I.) But physicist-turned-virus-researcher Richard Neher of the University of Basel and statistics professors Will Fithian of University of California at Berkeley and Andrew Gelman of Columbia University all argued that the statistical adjustments in the paper were outright wrong, with Gelman concluding on his blog that the authors of the paper “owe us all an apology. We wasted time and effort discussing this paper whose main selling point was some numbers that were essentially the product of a statistical error.”No such apology has been forthcoming, but the authors did on Thursday replace the paper on MedRxiv with a revised version that changed their estimate of the percentage of county residents infected with the virus to a range of 1.3% to 4.7%, and generally did much more to show their work and stress the uncertainty inherent in their findings. They also expressed appreciation for the many criticisms the paper had received, concluding that, “We feel that our experience offers a great example on how preprints can be an excellent way of providing massive crowdsourcing of helpful comments and constructive feedback by the wider scientific community in real time for timely and important issues.”Other scientists weren’t so sure the rough-and-tumble — and public — discussion around the paper was such a good thing. Two prominent medical school professors wrote an opinion piece for the science news site Stat decrying some of the criticisms as “ad hominem,” while Neeraj Sood of the University of Southern California, lead author of a related study in Los Angeles County that hasn’t been released as a preprint although preliminary results have been shared, told BuzzFeed’s Lee that “I don’t want ‘crowd peer review’ or whatever you want to call it. It’s just too burdensome and I’d rather have a more formal peer review process.”But is a more formal peer review really better? “To me there’s no doubt that more eyes on something mean that ultimately a better judgment can be made,” says MedRxiv’s Sever, a molecular biologist with long experience in editing scientific journals.Journals send articles to two or three people, ask for comments in two weeks, and the reviewers never do it on time and you have to pester them. The chance you get a representative sample is not that great. Wouldn’t it be great if there were a lot of other discussions that had already happened that journals could incorporate in their evaluation?Who’s Going to Pay for All of This?This implies a world in which open research-distribution channels and peer-reviewed journals exist side by side, playing different roles — which is how things have worked for quite a while in some academic disciplines. “In the old days, journals were viewed as a means of disseminating ideas,” Yale economist Pinelopi Goldberg, then the editor in chief of the American Economic Review, said at a conference I attended four years ago. “The most important function that journals have these days is the certification of quality.” Or as the saying supposedly goes (according to Sever), “Nobody ever got a job by putting something on ArXiv.”Academic journal publishing is dominated by a handful of for-profit publishers — the largest is Elsevier, a subsidiary of London-based RELX Plc — who sell digital access to their journals in large bundles to university libraries. Medical publishing is a bit different, with many leading journals controlled by nonprofit medical societies and distributed widely among practitioners, but they too rely heavily on subscription paywalls. Keeping scientific research that is funded by philanthropies, universities and government agencies behind such paywalls has been unpopular for a while, and has been coming under increasing pressure from those who pay for the research, especially in the European Union. Publishers and universities have been exploring new “read and publish” contracts in which universities pay both for access to the journals and paywall-free publication of articles by their faculty, but as the consequences of the coronavirus hammer budgets, sharp cutbacks in library spending on journals seem inevitable. “Those kinds of reckonings are coming very quickly,” says Joseph.Then again, these reckonings could endanger newer forms of scientific communication as well. Although preprint servers don’t cost nearly as much to run as academic journals — ArXiv has expenses of about $2.7 million a year, while the American Association for the Advancement of Science, publisher of the interdisciplinary journal Science, reports journal-and-publishing-related expenses for 2018 of more than $45 million — most(2) have to rely on the generosity of philanthropists and universities to pay the bills, and will struggle to make ends meet in a time of higher-education cutbacks. As scientific-publishing veteran Kent Anderson wrote in his subscription newsletter last week:Open science, which is essentially a basket of new expenses with no established funding models, isn’t going to suddenly receive millions or billions from the EU or some consortia of universities. So, hit the “pause” button here.One can imagine the pause button being hit for many aspects of scientific research in the coming months and years. There surely won’t be a shortage of funding for those who study viruses, pandemics and the like, but many other fields could face tough times. In some disciplines this may push scholars toward more open, collaborative ways of doing research and communicating it; in others it may reduce experimentation and communication. The scientific community is not a monolith. But on the whole, it does seem to be moving in a new direction.(1) Both MedRxiv and ArXiv spell their names with a lowercase first letter, but I've capitalized them here because that's what you're supposed to do with proper nouns.(2) Not all: The Social Science Research Network, a major preprint server for economics, the law and other fields, is owned by Elsevier.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Justin Fox is a Bloomberg Opinion columnist covering business. He was the editorial director of Harvard Business Review and wrote for Time, Fortune and American Banker. He is the author of “The Myth of the Rational Market.”For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • New Loss Correlation Study From LexisNexis Risk Solutions Reveals Use of In-Line Water Shutoff Reduces Escape-of-Water Home Insurance Claims by 96%
    PR Newswire

    New Loss Correlation Study From LexisNexis Risk Solutions Reveals Use of In-Line Water Shutoff Reduces Escape-of-Water Home Insurance Claims by 96%

    LexisNexis® Risk Solutions, a global data and advanced analytics leader, today released an insurance claims study revealing that in-line water shutoff systems correlate with a decrease in water claims events by 96%. Further underscoring the value of incorporating smart home technology, the study also found that those without water shutoff systems reported a 10% increase in water claims events over the same time period. The study measured changes in the number and severity of water-related home insurance claims with the Flo by Moen Smart Water Shutoff device against an uninstalled control group of homes in the same geolocation one year before and after installation.

  • New Strong Buy Stocks for May 5th
    Zacks

    New Strong Buy Stocks for May 5th

    New Strong Buy Stocks for May 5th

  • U.K. Corporate Titans Get Extra Time at Top in Virus Crisis
    Bloomberg

    U.K. Corporate Titans Get Extra Time at Top in Virus Crisis

    (Bloomberg) -- Some of London’s most influential investors are giving U.K. companies extra time to find new board members because of the coronavirus crisis, potentially offering a group of long-standing chairmen an unexpected extension to their careers.Legal & General Investment Management will allow London-listed companies an additional 12 months to replace directors coming to the end of their recommended tenures, it said in response to Bloomberg queries.That could affect companies ranging from wireless giant Vodafone Group Plc to $5 billion packaging producer DS Smith Plc, whose chairmen are close to the maximum nine-year length of service laid out in the U.K.’s guidebook for strong governance.“As a long-term investor, LGIM will be flexible in its policies,” said Angeli Benham, an environmental, social and governance manager at the investment firm, which oversees about 1.1 trillion pounds ($1.4 trillion) globally. “We acknowledge that the current environment may hamper the nominations committee’s ability to appoint the best candidates.”There are 15 companies in the FTSE 350 Index with a combined market value of about $130 billion where the chairman is due for a change after being in position for eight to 10 years, according to data compiled by Bloomberg.LGIM’s views hold sway, as it’s the biggest U.K. fund manager by assets and a dominant voice on corporate governance. The firm holds average stakes of about 2.5% in the country’s biggest companies.Extra TimeIt joins Federated Hermes Inc., which has also modified its voting policies for the 2020 season of shareholder meetings in light of the Covid-19 pandemic.“Companies facing unprecedented challenges require strong and stable leadership,” Hans-Christoph Hirt, the asset manager’s head of equity ownership services, wrote in an April 15 letter to listed company executives. “We will therefore be more flexible around the re-election of key directors to avoid unplanned disruption to board composition at this critical time.”RELX Plc, the $43 billion publisher that owns the LexisNexis database, said last month that it will take longer than expected to find a new chairman. The company first announced in February that Anthony Habgood, 73, had decided to retire from the board after more than a decade at the helm.“I don’t think there’s a huge demand to move on with this process right now,” Paul Abrahams, a spokesman for RELX, said by phone. “Anthony’s track record of value creation has been exceptional.”Seeking ContinuityAircraft parts supplier Meggitt Plc is also postponing a change, telling investors in March that chairman Nigel Rudd will stay until further notice to provide continuity during the Covid-19 outbreak. Rudd, who was appointed in 2015, had announced the previous month that he plans to step down after a successor is found.Other companies are in the process of hunting for candidates. Vodafone said in May last year it’s seeking a successor for Gerard Kleisterlee, who will hit nine years as chairman this July. DS Smith also announced last year it would seek a replacement for chairman Gareth Davis, whose term ends in January 2021. Intertek Group Plc, the $9 billion certification firm, is also due to find a new chairman as incumbent David Reid has been in place for more than eight years.A spokesperson for Vodafone said a search is ongoing, while representatives for DS Smith and Intertek declined to comment.Diversity PushThe hunt for fresh talent comes at a time when U.K. companies have been called out for their lack of female directors. Companies need people with new ideas and different experiences to make the best decisions in coming months, said Denise Wilson, chief executive officer of the Hampton-Alexander Review.There were twenty female chairmen of FTSE 250 companies as of October last year, up from 11 in 2017, according to the group, which lobbies for increased female representation on U.K. boards.“The coronavirus must not be used as an excuse to halt progress on improving gender diversity on boards,” said Brenda Trenowden, a partner at PwC U.K. and global co-chair of the 30% Club, the diversity campaign group. “It is important to keep a new generation of chairs coming through despite the difficult challenges businesses are obviously facing.”Peter Grauer, the chairman of Bloomberg News’s parent company Bloomberg LP, is the founding chairman of the U.S. chapter of the 30% Club.Establishing RapportThe Financial Reporting Council, the industry body that sets the U.K. Corporate Governance Code, requires companies that don’t comply with its director tenure limits to explain their reasons to investors. The code, which has been around in various forms since 1992, exists to help ensure chairmen and non-executive directors effectively carry out independent scrutiny of a company’s management.A representative for the FRC said there has been no change to its guidelines since the coronavirus outbreak.Some companies keep board members longer than recommended even during normal times. Pub owner Mitchells & Butlers Plc said in December that chairman Bob Ivell will stay past the usual limit, as it believes his industry knowledge is “invaluable” and his tenure hasn’t impacted his independence. Tim Martin, chairman of rival bar operator J D Wetherspoon Plc, has been in his role for more than 37 years.Search processes for new chairmen continue, though companies are holding off from actually making appointments, according to Will Dawkins, who leads the U.K. board practice at recruitment firm Spencer Stuart.“It’s very hard to establish that relationship with the CEO without actually meeting,” Dawkins said. “It’s common sense for chairs to stay on for a little more time at the moment, so long as there are no other difficulties within the company.”(Updates with details of board diversity push from 14th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • LexisNexis Risk Solutions Launches COVID-19 National Data Resource Center
    PR Newswire

    LexisNexis Risk Solutions Launches COVID-19 National Data Resource Center

    The Health Care business of LexisNexis® Risk Solutions has launched a free COVID-19 Data Resource Center to provide county-level insights on at-risk populations and potential care capacity gaps to support the U.S. healthcare industry's response to the COVID-19 pandemic. By combining its own data and analytics with those of other industry stakeholders, the company created insights that can be used by healthcare organizations, public health officials, and health researchers to help allocate resources to the populations with the greatest need.

  • Will RELX Continue to Surge Higher?
    Zacks

    Will RELX Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor RELX

  • RELX PLC's (LON:REL) Could Be A Buy For Its Upcoming Dividend
    Simply Wall St.

    RELX PLC's (LON:REL) Could Be A Buy For Its Upcoming Dividend

    It looks like RELX PLC (LON:REL) is about to go ex-dividend in the next 3 days. You will need to purchase shares...

  • Here's Why We Think RELX (LON:REL) Is Well Worth Watching
    Simply Wall St.

    Here's Why We Think RELX (LON:REL) Is Well Worth Watching

    Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...

  • Reuters

    Britain's Relx scraps guidance on hit to exhibitions business

    European information group Relx said it could not provide full-year guidance for the group due to the significant impact the coronavirus pandemic was having on its exhibitions arm. The group said its remaining business units, covering science, risk and legal, had only seen a limited impact from COVID-19 in the first quarter although they could be affected by changes in the customer market. The Exhibitions business, which accounted for 16% of revenue and 13% of adjusted operating profit in 2019, is being impacted significantly by COVID-19, it said, making its outlook highly uncertain.

  • Business Wire

    Trading Statement

    In our three largest business areas, Scientific, Technical & Medical, Risk & Business Analytics, and Legal, which together accounted for 84% of revenue and 87% of adjusted operating profit in 2019, the rate of underlying revenue growth in the first quarter of 2020 was slightly higher than in the same period of the prior year. The year to date underlying revenue growth rate is slightly higher than in the same period of the prior year.

  • Financial Services Firms Spend $180.9 Billion on Financial Crime Compliance, According to LexisNexis Risk Solutions Global Study
    PR Newswire

    Financial Services Firms Spend $180.9 Billion on Financial Crime Compliance, According to LexisNexis Risk Solutions Global Study

    Today, LexisNexis® Risk Solutions released its True Cost of Financial Crime Compliance Global Report, which provides global industry-driven insights for financial services firms across the Asia Pacific (APAC) region, Europe, the Middle East and Africa (EMEA), Latin America (LATAM) (including Mexico) and the U.S. and Canada. The report reveals that the projected total cost of financial crime compliance in these markets amounts to $180.9 billion.

  • Large Retail Pharmacy Chain Chooses LexisNexis Risk Solutions for Universal Patient Identifier
    PR Newswire

    Large Retail Pharmacy Chain Chooses LexisNexis Risk Solutions for Universal Patient Identifier

    LexisNexis® Risk Solutions has partnered with one of the largest nationwide retail pharmacy chains to provide the LexID® unique patient identifier across pharmacy operations to centralize records, reduce costs, and make quality healthcare easier to obtain for the pharmacy customers. The company also selected the LexisNexis® Keep Contact™ solution to maintain accuracy of demographic information for enhanced outreach and engagement in its wellness market.

  • LexisNexis Risk Solutions Releases New Index to Gauge Trends in Auto Insurance Shopping
    PR Newswire

    LexisNexis Risk Solutions Releases New Index to Gauge Trends in Auto Insurance Shopping

    LexisNexis® Risk Solutions today announced the launch of its new Insurance Demand Meter, which tracks automotive insurance shopping activity on a quarterly basis. The meter provides insurance carriers with valuable data to help benchmark their customers' auto insurance shopping volumes and patterns to those of the industry. With a more thorough understanding of how the economy, macro trends and current events impact consumer insurance shopping habits, carriers can identify unique insights and opportunities to strengthen their acquisition and retention strategies in order to gain a competitive advantage.

  • Chandler fraud prevention startup acquired in reported $500M deal
    American City Business Journals

    Chandler fraud prevention startup acquired in reported $500M deal

    Emailage is a fast-growing software-as-a-service company that provides global fraud prevention and identity verification to banks, airlines, e-commerce sites and other companies. Its CEO told the Business Journal that in light of the spread of the coronavirus, getting this buyout behind him is an "amazing closure."

  • New Strong Buy Stocks for March 25th
    Zacks

    New Strong Buy Stocks for March 25th

    New Strong Buy Stocks for March 25th

  • LexisNexis Risk Solutions Announces Emailage Acquisition Close
    PR Newswire

    LexisNexis Risk Solutions Announces Emailage Acquisition Close

    Global data and advanced analytics leader LexisNexis® Risk Solutions, part of RELX, announced today that it has closed the acquisition of Emailage, the Arizona-based fraud prevention and risk management solutions provider. Emailage provides fraud risk scoring solutions based on email intelligence.

  • LexisNexis Risk Solutions Adds Additional Fraud Risk Signal to LexisNexis ThreatMetrix with Behavioral Biometrics
    PR Newswire

    LexisNexis Risk Solutions Adds Additional Fraud Risk Signal to LexisNexis ThreatMetrix with Behavioral Biometrics

    LexisNexis® Risk Solutions today announced that it has added LexisNexis® Behavioral Biometrics to its portfolio of fraud and identity solutions. Behavioral Biometrics combined with existing digital identity intelligence enables organizations to make more reliable fraud and risk decisions.

  • Hedge Funds Have Never Been More Bullish On Relx PLC  (RELX)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Relx PLC (RELX)

    Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

  • LexisNexis Risk Solutions and iPipeline Join Forces to Deliver Low-Code Innovative Digital Solutions to Life Insurance Companies
    PR Newswire

    LexisNexis Risk Solutions and iPipeline Join Forces to Deliver Low-Code Innovative Digital Solutions to Life Insurance Companies

    LexisNexis® Risk Solutions and iPipeline today announced the integration of several LexisNexis data solutions into iPipeline's SSG Digital® platform for the iGO® e-App and Resonant® New Business and Underwriting products, providing even more ways to improve the experience of purchasing life insurance.

  • Should You Be Pleased About The CEO Pay At RELX PLC's (LON:REL)
    Simply Wall St.

    Should You Be Pleased About The CEO Pay At RELX PLC's (LON:REL)

    Erik Engstrom has been the CEO of RELX PLC (LON:REL) since 2009. First, this article will compare CEO compensation...

  • LexisNexis Risk Solutions Report Highlights Size, Scale and Monetary Exposure of Global Cybercrime Networks
    PR Newswire

    LexisNexis Risk Solutions Report Highlights Size, Scale and Monetary Exposure of Global Cybercrime Networks

    LexisNexis® Risk Solutions today released its Cybercrime Report covering July 2019 through December 2019.

  • LexisNexis Risk Solutions and Clarify Health Partner to Evaluate Predictive Capability of Social Determinants of Health and Clinical Data
    PR Newswire

    LexisNexis Risk Solutions and Clarify Health Partner to Evaluate Predictive Capability of Social Determinants of Health and Clinical Data

    LexisNexis® Risk Solutions announced a collaboration with Clarify Health, a leading healthcare analytics company that provides AI-driven market intelligence and predictive analytics business applications to health systems, health plans, and life sciences companies. The partnership will enable Clarify Health to use LexisNexis Risk Solutions socioeconomic data to better understand patient populations. The goal is to leverage the LexisNexis Risk Solutions clinically validated social and behavioral determinants of health data, sometimes referred to as "SDOH" attributes, within predictive models that currently utilize clinical data to improve health outcomes, reduce costs and prevent readmissions.